Vita Longa
  • Company
  • Products
    • Galebiron
    • Predneau
    • Torvastin
    • Drosone
    • Lycis
  • Contact us
  • English
  • Greek
Articles

Multiple Myeloma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

July 30, 2020 1:13 pmJuly 30, 2020

© 2020 VitaLonga

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download [463.21 KB]

Previous ArticleManagement of Toxicities from Immunotherapy: ESMO Clinical Practice GuidelinesNext ArticleEuropean Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
site footer menu
ΕΣΠΑ banner links to pdf document

Recent

  • Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings July 30, 2020
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma July 30, 2020

RSS esmo.org

  • Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma December 18, 2024

20, EL. VENIZELOU & YMITTOY STR, ATHENS, METAMORFOSI , 144 52
Phone.:  +30 210 3240020
Fax: +30 210 3240022
e-mail: info@vitalonga.gr
Map

Menu
  • Company
  • Products
    • Galebiron
    • Predneau
    • Torvastin
    • Drosone
    • Lycis
  • Contact us
  • English
  • Greek

site footer menuLogo Header Menu

  • Company
  • Products
    • Galebiron
    • Predneau
    • Torvastin
    • Drosone
    • Lycis
  • Contact us
  • English
  • Greek